Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease

被引:63
作者
Bryan, Kathryn J. [4 ]
Zhu, Xiongwei [4 ]
Harris, Peggy L. [4 ]
Perry, George [2 ,4 ]
Castellani, Rudy J. [3 ]
Smith, Mark A. [4 ]
Casadesus, Gemma [1 ]
机构
[1] Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA
[2] Univ Texas San Antonio, Coll Sci, San Antonio, TX USA
[3] Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA
[4] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1186/1750-1326-3-13
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Alzheimer disease (AD) is a chronic neurodegenerative disease that is characterized by progressive memory loss. Pathological markers of AD include neurofibrillary tangles, accumulation of amyloid-beta plaques, neuronal loss, and inflammation. The exact events that lead to the neuronal dysfunction and loss are not completely understood. However, pro-inflammatory cytokines, such as interleukin-1 beta, interleukin-6, and tumor necrosis factor a, are increased in AD, along with gene expression of major histocompatibility complex (MHC) class II molecules and macrophage migration inhibitory factor (MIF). MHC class II molecules are found in microglia of the brain, while MIF is found in both microglia and neurons of the hypothalamus, hippocampus, and cortex. MIF is not only a lymphocyte mediator but also a pituitary factor with endocrine properties and can mediate phosphorylation of the extracellular signal-regulated kinase-1/2 MAP kinases pathway. In this study, we looked at CD74, an integral membrane protein that acts as both a chaperone for MHC class II molecules as well as a receptor binding site for MIF. CD74 was recently found to be increased in microglia in AD cases compared to age-matched controls, but has not been reported in neurons. In our analysis, immunohistochemistry revealed a significant increase in CD74 primarily in neurofibrillary tangles, amyloid-beta plaques, and microglia. This is the first finding to our knowledge that CD74 is increased in neurons of AD cases compared to age-matched control cases.
引用
收藏
页数:5
相关论文
共 26 条
[1]   CD74 is a member of the regulated intramembrane proteolysis-processed protein family [J].
Becker-Herman, S ;
Arie, G ;
Medvedovsky, H ;
Kerem, A ;
Shachar, I .
MOLECULAR BIOLOGY OF THE CELL, 2005, 16 (11) :5061-5069
[2]  
Busser J, 1998, J NEUROSCI, V18, P2801
[3]   Neuroendocrine properties of macrophage migration inhibitory factor (MIF) [J].
Fingerle-Rowson, GR ;
Bucala, R .
IMMUNOLOGY AND CELL BIOLOGY, 2001, 79 (04) :368-375
[4]   Inflammatory processes in Alzheimer's disease [J].
Heneka, Michael T. ;
O'Banion, M. Kerry .
JOURNAL OF NEUROIMMUNOLOGY, 2007, 184 (1-2) :69-91
[5]   Involvement of prostaglandin E2 in production of amyloid-β peptides both in vitro and in vivo [J].
Hoshino, Tatsuya ;
Nakaya, Tadashi ;
Homan, Takashi ;
Tanaka, Ken-Ichiro ;
Sugimoto, Yukihiko ;
Araki, Wataru ;
Narita, Masami ;
Narumiya, Shuh ;
Suzuki, Toshiharu ;
Mizushima, Tohru .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (45) :32676-32688
[6]   Amyloid fibril formation by macrophage migration inhibitory factor [J].
Lashuel, HA ;
Aljabari, B ;
Sigurdsson, EM ;
Metz, CN ;
Leng, L ;
Callaway, DJE ;
Bucala, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 338 (02) :973-980
[7]   MIF signal transduction initiated by binding to CD74 [J].
Leng, L ;
Metz, CN ;
Fang, Y ;
Xu, J ;
Donnelly, S ;
Baugh, J ;
Delohery, T ;
Chen, YB ;
Mitchell, RA ;
Bucala, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (11) :1467-1476
[8]   Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease [J].
Lue, HQ ;
Kleemann, R ;
Calandra, T ;
Roger, T ;
Bernhagen, J .
MICROBES AND INFECTION, 2002, 4 (04) :449-460
[9]   Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease [J].
Mei, Matthew ;
Su, Bo ;
Harrison, Kristen ;
Chao, Mark ;
Siedlak, Sandra L. ;
Previll, Laura A. ;
Jackson, LaMia ;
Cai, Dan X. ;
Zhu, Xiongwei .
JOURNAL OF NEUROCHEMISTRY, 2006, 99 (05) :1377-1388
[10]   Elevated CSF prostaglandin E2 levels in patients with probable AD [J].
Montine, TJ ;
Sidell, KR ;
Crews, BC ;
Markesbery, WR ;
Marnett, LJ ;
Roberts, LJ ;
Morrow, JD .
NEUROLOGY, 1999, 53 (07) :1495-1498